Portfolio company
Amplifyer Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops humanised priming agents that increase circulating tumour DNA recovery to improve liquid biopsy sensitivity for cancer diagnostic providers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Fyr Bio
This company develops liquid biopsy diagnostic tools and biomarkers using extracellular vesicle enrichment technology for healthcare providers and pharmaceutical researchers.
SimSen Diagnostics
This company develops ultra-sensitive liquid biopsy tests to detect and monitor circulating tumour DNA for healthcare providers, research hospitals and pharmaceutical companies.
LiquidCell Dx
This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.
Amadix
This company develops blood-based liquid biopsy tests for the early detection of colorectal, lung and pancreatic cancer in patients and healthcare settings.
Amplifold
The company develops DNA-origami nanostructures for signal amplification in lateral flow assays for the in vitro diagnostics and life sciences sectors.
Avant Genomics
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
BioSkryb
This company develops genomic amplification and sequencing systems for researchers and clinicians to analyse DNA and RNA from single cells.
Amplified Sciences
This company develops molecular diagnostic tests and sensing platforms to help clinicians detect and monitor pancreatic cancer and other serious diseases in patients.
